Teva Pharmaceutical (NYSE:TEVA) has a few loose ends untied, from generics pressures to brand drug launches and pipelines that still need to prove themselves, before the Israeli pharma giant can make a comeback- at least in the eyes of Cantor analyst Louise Chen.
Story Continues
